Barinthus Biotherapeutics (STU:2AB) Net Income (Continuing Operations): €-45.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:2AB Barinthus Biotherapeutics PLC STU:2AB
14 GF Score
Price €0.55
GF Value €0.94
! 1 Warning Sign
View Full Analysis

What is Barinthus Biotherapeutics Net Income (Continuing Operations)?

Barinthus Biotherapeutics STU:2AB +4.76% 14 Net Income (Continuing Operations) is €-45.00 Mil as of Mar. 2026. GuruFocus rates STU:2AB with a GF Score™ of 14/100 and a GF Value™ of €0.94. The stock has 1 warning sign investors should review.

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Barinthus Biotherapeutics's Net Income (Continuing Operations) for the three months ended in Mar. 2026 was €-4.79 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2026 was €-45.00 Mil.

Barinthus Biotherapeutics  (STU:2AB) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Barinthus Biotherapeutics Net Income (Continuing Operations) Related Terms

Barinthus Biotherapeutics Net Income (Continuing Operations) Historical Data

* Premium members only.

The historical data trend for Barinthus Biotherapeutics's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Barinthus Biotherapeutics Net Income (Continuing Operations) Chart

Barinthus Biotherapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Income (Continuing Operations)
Get a 7-Day Free Trial -45.23 5.02 -67.35 -58.43 -56.76

Barinthus Biotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18.18 -18.32 -12.41 -9.48 -4.79
STU:2AB
14GF Score
Barinthus Biotherapeutics PLC STU:2AB
Net Income (Continuing Operations) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Barinthus Biotherapeutics Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-45.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income (Continuing Operations) of €-45.00 Mil mean?
Barinthus Biotherapeutics (STU:2AB) has a Net Income (Continuing Operations) of €-45.00 Mil as of Mar. 2026. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Barinthus Biotherapeutics and its competitors.
Is Barinthus Biotherapeutics' Net Income (Continuing Operations) too high?
Barinthus Biotherapeutics' current Net Income (Continuing Operations) is €-45.00 Mil. Overall, Barinthus Biotherapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Barinthus Biotherapeutics' Net Income (Continuing Operations) compare to VTGN and PSTV?
Barinthus Biotherapeutics' Net Income (Continuing Operations) of €-45.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income (Continuing Operations) for a Biotechnology company?
A good Net Income (Continuing Operations) depends on the Biotechnology industry context. However, Net Income (Continuing Operations) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income (Continuing Operations) mean?
A high Net Income (Continuing Operations) can signal that a stock is expensive relative to its fundamentals. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Barinthus Biotherapeutics and its competitors. Barinthus Biotherapeutics's current Net Income (Continuing Operations) is €-45.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Barinthus Biotherapeutics stock overvalued right now?
Barinthus Biotherapeutics (STU:2AB) has a current Net Income (Continuing Operations) of €-45.00 Mil. The stock's GF Value™ is €0.94, compared to a current price of €0.55 — trading 41.5% below its estimated fair value. The current Net Income (Continuing Operations) is €-45.00 Mil. Barinthus Biotherapeutics' overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income (Continuing Operations) calculated?
Net Income (Continuing Operations) is calculated from a company's financial statements. For Barinthus Biotherapeutics (STU:2AB), the current Net Income (Continuing Operations) is €-45.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Barinthus Biotherapeutics (STU:2AB) Overvalued in 2026?

Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued. The current stock price of €0.55 is trading 41.5% below its estimated GF Value™ of €0.94.

Key valuation signals for STU:2AB:

  • Net Income (Continuing Operations): €-45.00 Mil
  • GF Value™: €0.94 vs. price of €0.55 (41.5% below fair value)
  • GF Score™: 14/100 with 1 warning sign

No single metric tells the full story. See the STU:2AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Barinthus Biotherapeutics Business Description

Other Exchanges BRNS:USA
Address 20400 Century Boulevard, Suite 210, Germantown, MD, USA, 20874
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
14GF Score

Get the complete analysis for STU:2AB

Net Income (Continuing Operations) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.55
Price
€0.94
GF Value